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Abstract
Early diagnosis is important for type 2 diabetes (T2D) to improve patient prognosis, pre-
vent complications and reduce long-term treatment costs. We present a novel risk profiling
approach based exclusively on health expenditure data that is available to Belgian mu-
tual health insurers. We used expenditure data related to drug purchases and medical
provisions to construct models that predict whether a patient will start glucose-lowering
pharmacotherapy in the coming years, based on that patient’s recent medical expenditure
history. The design and implementation of the modeling strategy are discussed in detail
and several learning methods are benchmarked for our application. Our best performing
model obtains between 74.9% and 76.8% area under the ROC curve, which is comparable
to state-of-the-art risk prediction approaches for T2D based on questionnaires. In contrast
to other methods, our approach can be implemented on a population-wide scale at virtually
no extra operational cost. Possibly, our approach can be further improved by additional
information about some risk factors of T2D that is unavailable in health expenditure data.
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1. Introduction
Type 2 diabetes mellitus (T2D) is a chronic metabolic disorder characterized by hyper-
glycemia and is considered one of the main threats to human health (Zimmet et al., 2001).
In developed countries, T2D makes up about 85% of diabetes mellitus patients and occurs
when either insufficient insulin is produced, the body becomes resistant to insulin or both
(World Health Organization et al., 1994). Prediabetes and less severe cases of T2D are ini-
tially managed by lifestyle changes, specifically increasing physical exercise, dietary change
and smoking cessation (Tuomilehto et al., 2001; Diabetes Prevention Program Research
Group et al., 2002; American Diabetes Association et al., 2014). If this yields insufficient
glycemic control, pharmacotherapy with glucose-lowering agents (GLAs) like metformin or
insulin is started (Turner et al., 1999; American Diabetes Association et al., 2014).
Several studies have indicated that one third to one half of T2D patients are undiag-
nosed (Harris et al., 1998a; King et al., 1998; Rubin et al., 1994). Additionally, patients
often remain undiagnosed for extended periods of time, with average diagnose-free intervals
ranging from 4 to 7 years (Harris et al., 1992). The prognosis of untreated patients can
deteriorate rapidly as prolonged hyperglycemia can cause serious damage to many of the
body’s systems. Timely diagnosis of T2D proves challenging in contemporary medicine, as
many patients already present signs of complications of the disease at the time of clinical
diagnosis of T2D (Harris et al., 1998b; Rajala et al., 1998; Kohner et al., 1998; Ballard
et al., 1988; Harris and Eastman, 2000; Hu et al., 2002).
Earlier diagnosis and subsequent treatment is believed to prevent or delay complica-
tions and improve prognosis (Pauker, 1993; Engelgau et al., 2000). When impaired glucose
tolerance is diagnosed early, initial treatment can often be limited to lifestyle changes (Pan
et al., 1997; Tuomilehto et al., 2001; Diabetes Prevention Program Research Group et al.,
2002). Compared to pharmacotherapy, lifestyle changes are simple, fully manageable by
the patient and far less likely to cause serious treatment-induced complications like hypo-
glycemia (Seltzer, 1989; Zammitt and Frier, 2005). Complementary to health benefits, early
diagnosis of T2D poses a health economical advantage, as patients that do not require acute
or intensive long-term treatment are far less demanding on the health care system.
Universal screening for T2D is cost-prohibitive (Wareham and Griffin, 2001; Engelgau
et al., 2000), but many organizations advise opportunistic screening of high-risk subgroups
(World Health Organization et al., 1994; Alberti et al., 1998; Engelgau et al., 2000; Ameri-
can Diabetes Association et al., 2014). Several risk profiling strategies have been developed
to aid in the timely diagnosis of T2D (Baan et al., 1999; Stern et al., 2002; Lindstro¨m and
Tuomilehto, 2003; McNeely et al., 2003; Charlone et al., 2004; Heikes et al., 2008; Schwarz
et al., 2009). Risk profiling is typically done by assessing some of the key risk factors for
T2D, which include obesity (Mokdad et al., 2003), genetic predisposal (Shai et al., 2006;
Consortium et al., 2013), lifestyle (Reis et al., 2011) and various clinical parameters. Ex-
isting risk profiling approaches are implemented via questionnaires, potentially augmented
with clinical information that is available to the patient’s general practitionner (Griffin
et al., 2000; Spijkerman et al., 2004; Lindstro¨m and Tuomilehto, 2003; Glu¨mer et al., 2004;
Schulze et al., 2007; Heikes et al., 2008). Commonly required information includes BMI,
family history, exercise and smoking habits and various clinical parameters.
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In this work, we present an alternative approach for risk profiling which only requires
data that is already available to Belgian mutual health insurers. This work was done in
collaboration with the National Alliance of Christian Mutualities (NACM). NACM is the
largest Belgian mutual health insurer with over four million members. Our approach does
not require any questionnaires or additional clinical information and predicts whether a
patient will start taking GLAs in the next few years. Interestingly, our approach works well
despite the fact that Belgian health insurer data contains little direct information regarding
key risk factors of T2D, that is weight, lifestyle and family history are all unavailable.
2. Existing type 2 diabetes risk profiling approaches
The Cambridge Risk Score (CRS) was developed to assess the probability of undiagnosed
T2D based on data that is routinely available in primary care records, including age, sex,
medication use, family history of diabetes, BMI and smoking status (Griffin et al., 2000),
The CRS has been shown to be useful on multiple occasions (Griffin et al., 2000; Park et al.,
2002; Spijkerman et al., 2004), though its AUC seems to depend heavily on the population
in which it is used, ranging between 67% (Spijkerman et al., 2004) and 80% (Griffin et al.,
2000). The information used in the CRS is comparable to another approach which obtained
AUCs ranging between 70% and 78% (Baan et al., 1999).
The FINDRISC score is based on a 10-year follow-up using age, BMI, waist circum-
ference, history of antihypertensive drugs and high blood glucose, physical activity and
diet with reported AUCs of 85% and 87% in predicting drug-treated diabetes (Lindstro¨m
and Tuomilehto, 2003). The strongest reported predictors in this study were BMI, waist
circumference, history of high blood glucose and physical activity. Glu¨mer et al. (2004)
developed a risk score based on age, sex, BMI, known hypertension, physical activity and
family history of diabetes with AUC ranging from 72% to 87.6%. The German diabetes
risk score reached AUCs ranging from 75% to 83% on validation data and is based on age,
waist circumference, height, history of hypertension, physical activity, smoking, and diet
(Schulze et al., 2007).
Heikes et al. (2008) developed a decision tree for risk prediction achieving 82% AUC in a
cross-validation setting, based on weight, age, family history and various clinical parameters.
Various other approaches based on routine clinical information have demonstrated similarly
accurate predictions of type 2 diabetes (Stern et al., 2002; McNeely et al., 2003).
3. Health expenditure data
The Belgian health care insurance is a broad solidarity-based form of social insurance.
Mutual health insurers such as NACM are the legally-appointed bodies for managing and
providing the Belgian compulsory health care and disability insurance, among other things.
To implement their operations, Belgian mutual health insurers dispose of large databases
containing health expenditure records of all their respective members.
These expenditure records hold all financial reimbursements of drugs, procedures and
contacts with health care professionals. Each record comprises a timestamp, financial details
and a description of the claim. The financial aspect is irrelevant from a medical point of
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view, but the type of resource-use as indicated by the description can contain medical
information about the patient. These types belong to one of two main categories:
1. Drug purchases are recorded per package. The coding of packages contains infor-
mation about the active substances in the drug along with the volume of the package.
2. Medical provisions are identified by a national encoding along with an identifier of
the associated medical caregiver. Each provision has a distinct code number.
In addition to resource-use data, some biographical information is available about each
patient including age, gender, place of residence and social parameters. In the remainder
of this Section we will elaborate on expenditure records related to drugs and provisions.
Subsequently we will briefly summarize the main strengths and limitations of using health
expenditure data for predictive modeling.
3.1 Records related to drug purchases
Expenditure records concerning drug purchases contain information about the active sub-
stances in the drug and the purchased volume. We mapped all active substances onto the
anatomical therapeutic chemical (ATC) classification system maintained by the WHO Col-
laborating Centre for Drug Statistics Methodology (2015). The ATC classification system
divides active substances into different groups based on the organ or system on which they
act and their therapeutic, pharmacological and chemical properties. Each drug is classified
in groups at 5 levels in the ATC hierarchy: fourteen main groups (1st level), pharmaco-
logical/therapeutic subgroups (2nd level), chemical subgroups (3rd and 4th level) and the
chemical substance (5th level).
After mapping records onto the ATC classification system, a patient’s medication history
consists of specific ATC codes (5th level) along with the associated number of defined daily
doses (DDD). In the period of interest, purchases of 4,580 distinct active substances were
recorded in the NACM database. Table 1 shows an example of the classification of active
substance on all levels in the ATC system.
level ATC code description
1 A alimentary tract and metabolism
2 A10 drugs used in diabetes
3 A10B blood glucose lowering drugs, excluding insulins
4 A10BA biguanides
5 A10BA02 metformin
Table 1: Example of the ATC classification system: classification of metformin per level.
3.2 Records related to medical provisions
Expenditure records concerning medical provisions can be considered tuples containing
time-stamped identifiers of the patient, physician and medical provision. A single patient-
physician interaction may yield multiple such records, one for each specific provision that
occurred.
4
Predicting the Start of Glucose-Lowering Pharmacotherapy
In the Belgian health care system, medical provisions are encoded via the Belgian nomen-
clature of medical provisions (Van den Oever and Volckaert, 2008), which is maintained by
the National Institute for Health and Disability Insurance (NIHDI).1 This nomenclature is
an unstructured list of unique codes (numbers) for each provision that is being refunded.
Nomenclature numbers are added when new provisions are defined or when revisions are
made. A single provision may correspond to multiple numbers for various reasons.
3.3 Advantages of health expenditure data
The key benefit of expenditure databases is that they centralize structured medical informa-
tion across all medical stakeholders to yield a comprehensive, longitudinal overview of each
patient’s medical history. Other health data sources are fragmented, e.g. medical records
maintained by the patient’s general practitioner or hospital often contain only a subset of
the patient’s medical history. This fragmentation hampers the identification of patterns
that may indicate elevated risk for diseases like type 2 diabetes. The NACM database
comprises claims records of over four million Belgians, which enables complex modeling.
Additionally, claims data have few omissions due to the financial incentive for patients and
medical stakeholders (hospitals) to claim refunds. While other health data sources may
contain more detailed information, the strength of NACM’s data is in its volume, both in
terms of number of patients and the amount of information that is recorded per individual.
Finally, as most people tend to stay affiliated with the same mutual health insurer, their
expenditure records provide long-term information.
3.4 Limitations of health expenditure data
Belgian health expenditure data is strictly limited to what is required for mutual health
insurers to implement their operations, which are mainly administrative in nature. Detailed
health information such as diagnoses and test results are not directly available. In some
other countries, health insurers dispose of more detailed information, such as ICD-10 codes
which include diagnoses and symptoms (World Health Organization et al., 2012). Including
such information is out of scope of this work as we focus exclusively on data that is already
available to Belgian mutual health insurers. Biographical information about patients does
not contain direct information about some important risk factors such as lifestyle, family
history and BMI, though this may be partially embedded indirectly in medical resource-use.
4. Methods
In this Section we define the prediction task and describe all its aspects: the overall setup
(Section 4.1), the data and its representation (Section 4.2) and the learning algorithms
(Section 4.3). Briefly, our aim is to predict which patients will start glucose-lowering phar-
macotherapy within the next 4 years, based on expenditure records of the previous 4 years.
Our key hypothesis is that patients with increased risk for T2D or those that are already
afflicted but not diagnosed have a different medical expenditure history than patients with-
out impaired glycemic control. We essentially use the start of GLA therapy as a proxy for
1. The website of NIHDI is available at http://www.riziv.fgov.be.
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diagnosis of (advanced) type 2 diabetes. This is reasonable since most patients that start
GLA therapy above 40 years old have T2D (World Health Organization et al., 1994).
We posed this task as a binary classification problem. Our classifiers produce a numeric
level of confidence that a given patient will start glucose-lowering pharmacotherapy. When
predicting a population, the outputs can be used to rank patients according to decreasing
confidence that the patients will start glucose-lowering therapy. Highly ranked patients
represent a high-risk subgroup which can be targetted for clinical screening.
The full learning setup is described in Section 4.1, involving different learning methods
and representations of patients’ expenditure data. Briefly, we used nested cross-validation to
obtain unbiased estimates of the predictive performance of each vectorization and learning
approach. Predictive performance of all models was quantified via (area under) receiver
operating characteristic (ROC) curves.
Data Our work is based on a subset of the expenditure records of NACM. All data extrac-
tions and analyses were performed at the Medical Management Department of the NACM
under supervision of the Chief Medical Officer. The other research partners received no per-
sonally identifiable information (including small cells) from NACM. The patient selection
and vector representations are described in detail in Section 4.2.
Class definitions The positive class was defined as patients that require GLAs for long-
term glycemic control.2 The negative class is then defined as patients that do not need
GLAs. Expenditure records related to GLAs were used to identify a set of known positives.
However, the absence of such records in a patient’s resource use history is not proof that
this patient has no need for GLAs. This subtle difference is crucial, because it is well known
that patients with impaired glycemic control or T2D often remain undiagnosed and hence
untreated for a very long time (Harris et al., 1998a; King et al., 1998; American Diabetes
Association et al., 2014). As we cannot identify negatives, we had to build models from
positive and unlabeled data.
PU learning Learning binary classifiers from positive and unlabeled data (PU learning) is
a well-studied branch of semi-supervised learning (Lee and Liu, 2003; Elkan and Noto, 2008;
Mordelet and Vert, 2014; Claesen et al., 2015b). PU learning is more challenging than fully
supervised binary classification, since it requires special learning approaches and quality
metrics for hyperparameter optimization that account for the lack of known negatives. We
benchmarked three PU learning methods, which are discussed in more detail in Section 4.3.
Software The entire data analysis pipeline was implemented using open-source software.
For general data transformations and preprocessing we used SciPy and NumPy (Jones
et al., 2001; Van Der Walt et al., 2011). The learning algorithms we used are available in
scikit-learn and EnsembleSVM (Pedregosa et al., 2011; Claesen et al., 2014b) . Finally, we
used Optunity for automated hyperparameter optimization (Claesen et al., 2014a).
4.1 Experimental setup
We gathered all expenditure records during the 4-year interval of 2008 up to 2012. The se-
lection protocol and representations of patients’ medical resource-use are discussed in detail
2. GLAs are defined as any drug in ATC category A10, which includes metformin, sulfonylurea and insulin.
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in Section 4.2. All vector representations of patients include age (in years), an indicator
variable for gender and positive entries related to the patient’s medical resource-use. A
patient vector p can be written in the following general form, where dmeds and dprovs denote
the number of features in the vectorization of medication and provision use, respectively:
p ∈ R2+dmeds+dprovs+ =
[
age gender medication provisions
R+ {0, 1} Rdmeds+ Rdprovs+
]
. (1)
In Sections 4.2.1 and 4.2.2 we explain how records related to medication purchases and
provisions were represented in vector form. All entries in the vector representations were
consistently normalized to the interval [0, 1] by dividing feature-wise by the 99th percentile
and subsequently clipping where necessary. These normalized vector representations are
used as inputs for the learning algorithms described in Section 4.3.
Figure 1 summarizes the full machine learning pipeline, which starts from expendi-
ture records and ends with models to predict whether a patient will start glucose-lowering
pharmacotherapy along with an estimate of their generalization performance. We used
nested cross-validation to estimate generalization performance of different learning config-
urations (Varma and Simon, 2006). The outer 3-fold cross-validation is used to estimate
generalization performance of the full learning approach. Internally, twice iterated 10-fold
cross-validation was used to find optimal hyperparameters for every learning method.
Hyperparameter search We used Optunity’s particle swarm optimizer to identify suit-
able hyperparameters for each approach based on the given training set as defined by the
outer cross-validation procedure (Claesen et al., 2014a). Every tuple of hyperparameters
was evaluated using twice iterated 10-fold cross-validation on the training set. Per tech-
nique, the hyperparameters that maximized cross-validated performance were selected and
used to train a model on the full training set.
Model evaluation Models are compared based on area under the ROC curve. ROC
curves visualize a classifier’s performance spectrum by depicting its true positive rate
(TPR)3 as a function of its false positive rate (FPR)4 while varying the decision threshold
to decide on positives. Area under the ROC curve (AUROC) is a useful summary statistic
of a classifier’s performance. AUROC is equal to the probability that the classifier ranks
a random positive higher than a random negative and is known to be equivalent to the
Wilcoxon test of ranks (Hanley and McNeil, 1982).
Computing ROC curves Full label knowledge is required to compute ROC curves. In
previous work, we introduced a method to compute bounds on ROC curves based on positive
and unlabeled data (Claesen et al., 2015a). Briefly, it is based on the positions of known
positives in a ranking produced by a given classifier and requires two things:
• The rank distributions of labeled and latent positives must be comparable. This holds
when known and latent positives follow the same distribution in input space (ie. the
vector representation of patients). This is a fair assumption in our application, since
we specifically ignore records after the start of glucose-lowering pharmacotherapy
3. TPR measures the fraction of true positives that are correctly identified by the classifier.
4. FPR measures the fraction of true negatives that are incorrectly identified by the classifier.
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patient labels y age and gender drug records provision records
medication vectorization
maps onto Rdmeds+
provision vectorization
maps onto Rdprovs+
data matrix X
each row ∈ R2+dmeds+dprovs+ =
[
age gender medication provisions
R+ {0, 1} Rdmeds+ Rdprovs+
]
feature-wise normalization: all inputs are scaled to the interval [0, 1]
scaled data matrix Xscaled
outer cross-validation (3-fold on Xscaled and y):
1. determine folds based on labels y
2. loop:
• determine train and test data X(outer)train , X(outer)test
• build model on X(outer)train with associated labels
• test model on X(outer)test with associated labels
3. aggregate performance estimates across folds
1. determine optimal hyperparameters λ∗
• optimize area under ROC curve
• estimated using 2× 10-fold
cross-validation on X
(outer)
train and
its associated labels
• via particle swarm optimization
2. train model with λ∗ on X(outer)train
performance estimates
ROC and PR curves
optimized models
feature importance
Figure 1: Overview of the full learning approach: data set vectorization, normalization and
the nested cross-validation setup. Per iteration, hyperparameter optimization
and model training is done based exclusively on X
(outer)
train .
while identifying the set of positives (see Section 4.2), so the medication regimen of
known positives has not yet diverged from the regimen of untreated patients.
• An estimate βˆ of the fraction of latent positives in the unlabeled set is needed, that
is the fraction of members that have never used GLAs but are likely to start glucose-
lowering pharmacotherapy. In the period 2010–2014 roughly 8% of members of NACM
aged 40 or higher started using GLAs. Underestimating βˆ results in an underestimated
ROC curve and vice versa (Claesen et al., 2015a). We opted to be conservative and
used βˆlo = 5% to estimate lower bounds and βˆup = 10% for upper bounds.
We consistently used the lower bounds for hyperparameter search. All our performance
reports contain lower and upper bounds, based on βˆlo and βˆup, respectively.
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Diagnosing overfitting In addition to measuring performance, we diagnosed overfitting
via the concept of rank distributions as defined by Claesen et al. (2015a). The rank distri-
bution of a subset of test instances is defined as the distribution of the positions of these
test instances in a ranking of the full test set based on a model’s predicted decision values.
We diagnose overfitting based on the rank distributions of known positive training instances
(Ptrain) and known positives in the independent test fold (Ptest) after predicting the full
data set. If the model overfits, the rank distribution of Ptrain is inconsistent with the rank
distribution of Ptest. Specifically, ranks in Ptest are worse than those in Ptrain when the
model overfits. This can be quantified via the Mann-Whitney U test (Mann and Whitney,
1947) based on ranks of Ptrain and Ptest after predicting the full data set (that is all outer
folds). The Mann-Whitney U test is expected to yield a non-significant result when the
rank distributions of Ptrain and Ptest are comparable. We report the average p-values of the
test across outer cross-validation folds for each model (low p-values indicate overfitting).
4.2 Data Set Construction
We constructed a data set containing records of patients born before 1973 (e.g. 40 or more
years old in 2012). Patients with records of glucose-lowering agents (GLAs) during less
than 30 days were discarded. Patients with records of glucose-lowering therapy prior to
2012 were discarded. Patients that joined NACM after 2005 were also discarded, as we
cannot determine whether these patients used GLAs in the recent past.
All patients that started glucose-lowering pharmacotherapy in 2012 or later are included
as known positives (n = 31, 066), along with unlabeled patients that were sampled at ran-
dom from the remaining NACM members (n = 79, 243). Known positives have a minimum
of 30 days between the first and last purchase of GLAs to avoid contaminating the data set
with false positives, for instance due to insulin use in surgical and medical ICUs (Van den
Berghe et al., 2001, 2006). It must be noted that some false positives remain, that is patients
that use GLAs but not for glycemic control.
In Sections 4.2.1 and 4.2.2 we describe the vector representations of records regarding
medication and medical provisions, respectively.
4.2.1 Representation of medication records
The simplest way to represent medication purchases during a time interval is by having
one input dimension per active substance (level 5 ATC codes) and counting the purchased
volume in terms of DDDs. This representation is easy to construct but fails to capture any
similarity between active substances, such as the system or organ on which they act.
Imposing structure We can directly use the hierarchical structure of the ATC system
to define a measure of similarity between drugs. To impose structure between drugs we
included input dimensions related to more generic levels of the ATC hierarchy (levels 1 to 4).
On more generic levels we summed all DDD counts of active substances per category (level
5). This redundancy allowed us to express similarity between different active substances
with a standard inner product. By normalizing every feature to the unit interval, we
obtained the desired effect that patients with comparable drug use on ATC level 5 are more
similar than patients that only share coefficients on more generic levels. Figure 2 illustrates
this vector representation of trees and the effect of normalization.
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αA1 = 7
βA1 = 1
γA1 = 1 γ
A
2 = 0
βA2 = 5
γA3 = 3 γ
A
4 = 2
βA3 = 1
γA5 = 1 γ
A
6 = 0
PATIENT A: TREE
PATIENT A: VECTOR
VA =
[
1.0 0.0 3.0 2.0 1.0 0.0 1.0 5.0 1.0 7.0
]
αB1 = 7
βB1 = 2
γB1 = 0 γ
B
2 = 2
βB2 = 3
γB3 = 1 γ
B
4 = 2
βB3 = 2
γB5 = 0 γ
B
6 = 2
PATIENT B: TREE
PATIENT B: VECTOR
VB =
[
0.0 2.0 1.0 2.0 0.0 2.0 2.0 3.0 2.0 7.0
]
S =
[
1.0 2.0 3.0 2.0 1.0 2.0 2.0 5.0 2.0 7.0
]
V?A =
[
1.0 0.0 1.0 1.0 1.0 0.0 0.5 1.0 0.5 1.0
]
V?B =
[
0.0 1.0 0.3 1.0 0.0 1.0 1.0 0.6 1.0 1.0
]
Figure 2: Visualization and vectorization of trees. In the tree representation, the value of
internal nodes is the sum of the values of its children. The unnormalized vector
representations VA and VB contain the values per node in the tree representation
in some fixed order. Inner products between unnormalized representations VA
and VB are mainly influenced by the top level nodes, since those have the largest
value by construction. This undesirable effect can be fixed through feature-wise
scaling. The scaling vector S was constructed using node-wise maxima. The
normalized vector representations V?A and V?B are obtained by dividing the vector
representations (VA, VB) element-wise by entries in the scaling vector S. V?A and
V?B are used as input to classifiers in the remainder of this work. As desired, the
inner product of normalized vector representations is increasingly influenced by
similarities at higher depths in the tree representations.
Summary All vectorizations related to drug purchases are described in Table 2.
vectorization description dmeds
atc 5 counts of DDDs per medication class in ATC level 5 4,580
atc 1–4 counts of DDDs per medication class in ATC levels 1–4 1,257
atc 1–5 counts of DDDs per medication class in ATC levels 1–5 5,837
Table 2: Summary of vectorization schemes used for records of drug purchases.
4.2.2 Representation of provision records
When considering a specific time period, we can describe records by a (sparse) three-
dimensional tensor containing frequency counts as illustrated in Figure 3. We filtered all
provisions with a description containing diabetes, insulin and glucose and provisions not
recorded with a physician identifier. After filtering, 5,799 distinct provision codes remain
(denoted by #provisions).
10
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Σ over physicians
and transpose
PATIENT MATRIX
#patients × #provisions
110,309 × 5,799
Σ over patients
PHYSICIAN MATRIX
#provisions × #physicians
5,799 × 118,554
Figure 3: Tensor formulation of medical provisions with three components: patients, physi-
cians and provisions. Each entry in the tensor is the frequency of the given tuple.
This provision tensor is very sparse. The patient matrix is obtained by sum-
ming counts over all physicians (transposed). The physician matrix is obtained
by summing counts over all patients. These matrices capture complementary
information.
Each patient is modelled by a histogram of their provisions in the period of interest.
This essentially means we compute the sum over the physician-component of the tensor
representation to obtain a matrix, in which rows and columns represent patients and pro-
visions, respectively. Unfortunately, the encoding of provisions has no medically relevant
structure in contrast to the ATC hierarchy for drugs as discussed in Section 4.2.1.
Imposing structure In order to define a reasonable similarity measure between patients,
we first had to impose a structure onto the nomenclature that captures similarity between
provisions. To structure provisions, we should not use information originating from the
patient matrix, as this may cause information leaks (since the patient matrix is used directly
in our models for prediction). Instead, we used the complementary physician matrix as a
basis to define similarity between provisions, which essentially serves as a proxy for the
medical specializations to which each provision belongs. We started from cosine similarity
between nomenclature codes based on the physician matrix. We used cosine similarity
because it is known to work well for text mining with bag-of-words representations, which
is comparable to our use case as it also features sparse, high dimensional input spaces. The
cosine similarity κcos between two row vectors u and v is defined as:
κcos(u,v) =
〈u,v〉
‖u‖ · ‖v‖ =
uvT
‖u‖ · ‖v‖ . (2)
Using cosine similarity we can construct a pair-wise similarity matrix Sprov between provi-
sions based on the rows of the physician matrix xi, i = 1..#provisions:
Sprov =
(
κcos(xi,xj)
)
ij
∈ R#provisions×#provisions. (3)
Sprov expresses similarity between provision codes based on the physicians that provide
them and can be regarded as a proxy for the medical subdomain each provision frequently
occurs in. In our context, its entries range from 0 (completely orthogonal) to +1 (exact
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similarity). To impose sparsity we set all entries of Sprov below 0.05 to 0. Its structure is
visualized in Figure 4, which clearly indicates that our approach successfully identifies some
coherent groups of provisions.
0.00
0.15
0.30
0.45
0.60
0.75
0.90
Figure 4: Structure of the provision similarity matrix Sprov based on providing physicians.
Finally, the structured representation of provisions Pstruct is defined as the matrix prod-
uct between the patient matrix Pflat and the provision similarity matrix Sprov:
Pstruct = Pflat × Sprov ∈ R#patients×#provisions. (4)
Pstruct approximately captures which provisions occur in a patient’s history with redun-
dancy based on medical specializations.
Summary All vectorizations related to medical provisions are described in Table 3.
vectorization symbol description dprovs
provs flat Pflat entries taken from the patient matrix 5, 799
provs struct Pstruct captures similarity between provisions 5, 799
provs both Pflat | Pstruct concatenation of flat & structured 11, 598
Table 3: Summary of vectorization schemes used for records of medical provisions.
4.3 Modeling approaches
Having only positive and unlabeled data (PU learning) presents additional challenges for
learning algorithms. Two broad classes of approaches exist to tackle these problems: (i)
two-phase methods that first attempt to identify likely negatives from the unlabeled set and
then train a supervised model on the positives and inferred negatives (Liu et al., 2002; Yu,
2005) and (ii) approaches that treat the unlabeled set as negatives with label noise (Elkan
and Noto, 2008; Lee and Liu, 2003; Mordelet and Vert, 2014; Claesen et al., 2015b).
We have tested three approaches from the latter category in this work, namely class-
weighted SVM (Liu et al., 2003), bagging SVM (Mordelet and Vert, 2014) and the robust
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ensemble of SVM models (Claesen et al., 2015b). All of these approaches are based on
support vector machines. We used the linear kernel on vector representations of patients as
described in Section 4.2.5 We will briefly introduce each method in the following subsections.
4.3.1 Class-weighted SVM
Class-weighted SVM (CWSVM) uses a misclassification penalty per class. CWSVM was
first applied in a PU learning context by Liu et al. (2003), by considering the unlabeled set
to be negative with noise on its labels. A CWSVM is trained to distinguish positives (P)
from unlabeled instances (U), leading to the following optimization problem:
min
α,ξ,b
1
2
N∑
i=1
N∑
j=1
αiαjyiyjκ(xi,xj) + CP
∑
i∈P
ξi + CU
∑
i∈U
ξi, (5)
s.t. yi(
N∑
j=1
αjyjκ(xi,xj) + b) ≥ 1− ξi, i = 1, . . . , N,
ξi ≥ 0, i = 1, . . . , N,
where α ∈ RN are the support values, y ∈ {−1,+1}N is the label vector, κ(·, ·) is the kernel
function, b is the bias term and ξ ∈ RN are the slack variables for soft-margin classification.
The misclassification penalties CP and CU require tuning. We used the implementation
available in scikit-learn (Pedregosa et al., 2011) based on LIBSVM (Chang and Lin, 2011).
4.3.2 Bagging SVM
In bagging SVM, random resamples are drawn from the unlabeled set and CWSVM classi-
fiers are trained to discriminate all positives from each resample (Mordelet and Vert, 2014).
Resampling the unlabeled set induces variability in the base models which is exploited via
bagging. Base model predictions are aggregated via majority voting.
Bagging SVM with linear base models has two hyperparameters, namely the size of
resamples of the unlabeled set nU and the misclassification penalty on unlabeled instances
CU . The misclassification penalty on positives CP is fixed via the following rule:
CP =
nU × CU
|P| , (6)
where |P| denotes the number of known positives. The heuristic rule in Equation 6 is
common in imbalanced settings (Cawley, 2006; Daemen et al., 2009). We implemented
bagging SVM using the EnsembleSVM library (Claesen et al., 2014b).
4.3.3 Robust ensemble of SVM models
The robust ensemble of SVM models (RESVM) is a modified version of bagging SVM in
which both the positive and unlabeled sets are resampled when constructing base model
training sets (Claesen et al., 2015b). The extra resampling induces additional variability
between base models which improves performance when combined with a majority vote
5. Though it must be noted that the ensemble methods are always implicitly nonlinear.
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aggregation scheme. Claesen et al. (2015b) demonstrated that resampling the positive
set provides robustness against false positives, which makes RESVM appealing for our
application since our data set is known to contain a small fraction of false positives (as
explained in Section 4.2).
When using linear base models, the RESVM approach has four hyperparameters that
must be tuned, namely resample sizes and misclassification penalties per class. This ap-
proach was implemented based on EnsembleSVM (Claesen et al., 2014b).
5. Results and discussion
Section 5.1 shows the predictive performance per learning configuration and compares these
performances to the current state-of-the-art in large-scale risk assessment for T2D. Sec-
tion 5.2 shows performance curves of the best configuration, which enable us to determine
suitable cutoffs to identify target groups in practice. Finally, Section 5.3 describes a simple
approach to assess which features contribute most to risk according to our best models.
5.1 Benchmark of learning methods
Table 4 summarizes the performance of each learning configuration. The age,gender
feature set provides a baseline for comparison, all other feature sets include these as well. As
shown in the results, this two-dimensional representation already carries some information.
RESVM bagging SVM class-weighted SVM
features AUROC (%) p AUROC (%) p AUROC (%) p
age, gender 55.74–56.64 ∗ 58.61–59.67 ∗ 60.96–62.21 0.04
atc 5 72.55–74.43 0.17 70.83–72.62 0.09 71.89–73.74 0.01
atc 1–4 73.12–75.07 0.07 69.57–71.24 ∗ 73.05–74.91 0.04
atc 1–5 74.34–76.27 0.13 71.50–73.27 0.05 72.13–73.94 ∗
provs flat 58.45–59.51 ∗ 60.74–61.92 ∗ 63.01–64.31 ∗
provs struct 57.40–58.39 0.02 59.53–60.58 0.01 62.53–63.81 0.01
provs both 58.89–59.75 ∗ 61.72–62.87 ∗ 63.45–64.75 ∗
atc | provs 74.89–76.82 0.04 69.72–71.40 ∗ 73.77–75.64 ∗
Table 4: Average bounds on area under the ROC curve and p-value of the Mann-Whitney
U test over all folds for different feature sets per learning approach in a long-
term prediction setup. The lower and upper bounds on AUC were computed
with βˆlo = 0.05 and βˆup = 0.10, respectively. The atc | provs feature set is the
concatenation of the best performing sets per aspect, namely atc 1–5 and provs
both. Stars (∗) denote p-values below 0.005.
Based on Table 4 we can conclude that a patient’s medication history is highly informa-
tive to predict the start of GLA therapy. Using features based on ATC level 5, the RESVM
model obtained an AUC between 72.55% and 74.43%. By adding redundancy as described
in Section 4.2.1 the performance based on medication history alone was further increased
to between 74.34% and 76.27% for the best learning approach (RESVM).
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Predictive performance based on provisions alone turned out fairly poor, showing only a
mild improvement compared to models based exclusively on age and gender for all learning
algorithms. Interestingly, the best approach for representations based on provisions was
class-weighted SVM, with RESVM being worst of all three learning methods. It appears
that for these representations, large training sets are better: class-weighted SVM uses the
full training set, bagging SVM uses all positives and a subset of unlabeleed instances per
base model and RESVM uses (small) subsets of both positives and unlabeled instances per
base model.
The best representation included age, gender, and structured information about drugs
and provision history of the patient. The best learning method on this representation was
RESVM, achieving an AUC between 74.89% and 76.82%. In Section 5.1.1 we compare the
performance of our approach to competing screening methods.
Finally, RESVM appears most resistant to overfitting in the hyperparameter optimiza-
tion stage as it consistently exhibits the highest average p-values in our diagnostic test
(higher is better, see Section 4.1). We believe this to be attributable to the use of small
resamples of both positives and unlabeled instances when training base models in RESVM,
since this makes it unlikely to obtain a structural overfit of the ensemble model on the full
training set. In contrast, bagging SVM is far more prone to overfitting because every base
model is trained on all positives.
5.1.1 Comparison to state-of-the-art
Our best approach obtained cross-validated AUC between 74.89% and 76.82% (exact num-
bers are unknown due to the lack of known negatives). This is comparable to many com-
peting approaches, based on questionnaires and some clinical information such as the Cam-
bridge Risk Score (AUC 67%–80%, (Spijkerman et al., 2004; Griffin et al., 2000)), the Danish
risk score (AUC 72%–87.6%, (Glu¨mer et al., 2004)), the German diabetes risk score (AUC
75%–83%, (Schulze et al., 2007)) and a Dutch approach (AUC 74%, (Baan et al., 1999)).
Approaches using detailed clinical information generally perform better, but are more ex-
pensive to maintain (Stern et al., 2002; McNeely et al., 2003; Lindstro¨m and Tuomilehto,
2003; Heikes et al., 2008). They key advantage of our approach is the fact it is easy to
implement on a population wide scale at virtually no operational cost.
The target class we used in this work is stricter than in the risk prediction methods
mentioned in Section 2, namely patients that require GLAs for glycemic control versus
patients with impaired glycemic control, respectively (except for Lindstro¨m and Tuomilehto
(2003), which also predicted drug-treated T2D). It is reasonable to assume that our models
generally rank patients with impaired glycemic control but without a need for GLAs higher
than patients without impaired glycemic control. In our performance assessment both
of these patient groups are essentially treated as negatives, in contrast to the screening
programmes mentioned previously which treat patients with impaired glycemic control as
positives. Hence, we believe the performance of our models would appear higher when
evaluated against a target class comprising all patients with impaired glycemic control, as
is done in the evaluation of other screening approaches. Unfortunately, we are unable to
accurately identify patients with impaired glycemic control but without need for GLAs.
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All competing methods use either clinical information or direct knowledge of risk factors
that is unavailable to us. Furthermore, the characteristics that are lacking in our data have
been reported to be the most informative to assess risk for T2D (Lindstro¨m and Tuomilehto,
2003; Stern et al., 2002; McNeely et al., 2003). We obtained generalization performances
that are comparable to existing approaches, despite these missing predictors. Finally, our
approach is the only one that is based exclusively on existing data that is always available,
without requiring additional patient contacts or clinical tests.
5.2 Receiver Operating Characteristic curves for RESVM
The RESVM model based on atc | provs vectorization had the best overall performance.
Figure 5 shows bounds on the ROC and PR curves for this model. These bounds were com-
puted using the technique described by Claesen et al. (2015a). The true curve is unknown
because we do not dispose of negative labels.
ROC curves enable us to determine a cutoff to use in practice, based on a suitable
balance between true and false positive rate (sensitivity and 1-specificity, respectively).
Determining a suitable balance requires a tradeoff between the relative importance of iden-
tifying undiagnosed patients (true positives) vis-a`-vis increased amounts of screening tests
on patients that are in fact healthy (false positives).
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Figure 5: Performance curves for the best model: RESVM classifier based on atc | provs
vectorization. The lower and upper bounds are estimated using βˆlo = 5% and
βˆup = 10%, respectively.
It should be noted that precision depends on class balance, and therefore the PR curve
shown in Figure 5(b) is not representative for screening an overall population, since the
overall population has a higher fraction of negatives than our custom data set (i.e. precision
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would be lower in practice). In contrast, the bounds in ROC space are representative because
ROC curves are insensitive to changes in class distribution (Fawcett, 2006).
5.3 Feature importance analysis for the RESVM model
The RESVM model is implicitly nonlinear due to its majority voting rule to aggregate
base model decisions, which poses problems in assessing the importance of each predictor.
However, our use of linear base models enables a simple approximation. The decision value
for base model i ∈ {1, . . . , nmodels} for a test instance z can be written as follows:
fi(z) = 〈wi, z〉+ ρi,
where wi is the separating hyperplane and ρi is a bias term. A simple linear approximation
of such ensemble models can be computed as the average of all base model hyperplanes:
w¯ =
nmodels∑
i=1
wi/nmodels.
Feature importance can then be determined based on the coefficients in w¯. Since we nor-
malized all features to the unit interval [0, 1] we can conclude that the features with largest
(positive) coefficients contribute most to risk as identified by our model.
Via this approach, the risk associated to use of cardiovascular medication (ATC main
category c) far outweights all other ATC main categories. This is not surprising, as diabetes
is known to be strongly related to cardiovascular problems (Kannel and McGee, 1979;
Grundy et al., 1999; Hu et al., 2002). The relative importance of features will be discussed
in detail in a subsequent medical paper.
6. Conclusion
In this work we have demonstrated the ability to predict clinical outcomes based solely
on readily available health expenditure data. We successfully built proof-of-concept clas-
sifiers to predict the start of glucose-lowering pharmacotherapy in patients above 40. Our
experiments show that accurate predictions can be made based on historical medication
purchases. These predictions can be further improved by incorporating information about
medical provisions and the use of appropriate vectorization schemes.
Since adult patients starting glucose-lowering pharmacotherapy are mainly afflicted with
type 2 diabetes (T2D), our models can be used for T2D risk assessment. Our approach
presents a novel method for case finding which can be easily incorporated in modern health-
care, since all required data is already available. The associated operational costs are very
low as the entire workflow can be fully automated without any need for patient contacts or
medical tests. As such, our work provides an efficient and cost-effective method to identify
a high risk subgroup, which can then be screened using decisive clinical tests.
Interestingly, our approach works well even though health expenditure data contains
very limited direct information on some important known risk factors. In that sense, our
approach is fundamentally different from the current state-of-the-art which mainly focuses
on quantifying known risk factors directly, either by asking the patient or through clinical
tests. The performance of our approach is expected to improve further when additional
information about these risk factors can be obtained, e.g. family history and lifestyle.
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